Table 2.

Summary of patient disposition for RP2D populations^a

	RCC Cohort Ibrutinib 840 mg + Everolimus N = 39	GC Cohort Ibrutinib 560 mg + Docetaxel N = 46	CRC Cohort Ibrutinib 840 mg + Cetuximab N = 50
Treatment duration, ibrutinib, median (range), months	2.8 (0.1–27.9)	2.5 (0.1–15.1)	3.2 (0.2–14.0)
Treatment duration of partner drug, median (range), months	3.1 (0.1–27.9)	2.1 (0.0–14.5)	3.0 (0.0–13.8)
Ibrutinib treatment disposition, n (%)
Still on treatment	0	0	0
Discontinued treatment	39 (100)	46 (100)	50 (100)
Primary reason for ibrutinib discontinuation, n (%)
Disease progression	22 (56)	29 (63)	35 (70)
Clinical deterioration	2 (5)	3 (7)	1 (2)
Adverse events	12 (31)	8 (17)	8 (16)
Death	0	0	1 (2)
Withdrawal of consent	2 (5)	4 (9)	4 (8)
Investigator decision	1 (3)	2 (4)	1 (2)
Companion drug treatment disposition, n (%)
Still on treatment	0	0	0
Discontinued treatment	39 (100)	46 (100)	50 (100)
Primary reason for discontinuation of companion drug, n (%)
Disease progression	22 (56)	26 (57)	32 (64)
Clinical deterioration	2 (5)	2 (4)	1 (2)
Adverse events	11 (28)	10 (22)	10 (20)
Death	0	0	1 (2)
Withdrawal of consent	3 (8)	4 (9)	4 (8)
Investigator decision	1 (3)	4 (9)	2 (4)

CRC colorectal adenocarcinoma, ECOG Eastern Cooperative Oncology Group, GC gastric adenocarcinoma, RCC renal cell carcinoma, RP2D Recommended phase 2 dose

^aData cutoff date: 19 April 2021